Prophase Labs, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OTC.Pink
ProPhase Labs' CEO and Chairman, Ted Karkus, was issued 500,000 warrants to purchase common stock at $0.60 per share following shareholder approval of an increase in authorized shares.
OTC.Pink
ProPhase Labs' Chief Operating Officer, Stuart Hollenshead, was granted stock options as an inducement award.
OTC.Pink
Director Warren Hirsch acquired options to purchase 100,000 shares of ProPhase Labs common stock on February 14, 2025.
OTC.Pink
Director Louis Gleckel acquired options to purchase 100,000 shares of ProPhase Labs stock on February 14, 2025.
OTC.Pink
Ted Karkus, CEO & Chairman of ProPhase Labs, files an amended Form 4 to correct the reporting of a 400,000 share option grant.
OTC.Pink
Director Jed Latkin acquired 500,000 stock options in ProPhase Labs, Inc. on January 1, 2024.
OTC.Pink
Director Warren Hirsch reports acquisition of 70,000 ProPhase Labs options exercisable at $6, vesting in quarterly installments.
OTC.Pink
Director Louis Gleckel acquired 70,000 stock options in ProPhase Labs, Inc. on March 17, 2024, which vest in quarterly installments over the next year.
OTC.Pink
Director Jason Barr acquired 70,000 stock options in ProPhase Labs, Inc. on March 17, 2024.
OTC.Pink
ProPhase Labs CEO and Chairman Ted Karkus reports the acquisition of 400,000 stock options on March 17, 2024.